In 2025, we performed one related bone marrow transplant and one peripheral blood stem cell transplant, and three unrelated bone marrow transplants and three umbilical cord blood transplants. The diseases treated were two cases of acute lymphoblastic leukemia, and one case each of acute myeloid leukemia, malignant lymphoma, aplastic anemia, congenital keratosis, Diamond-Blackfan anemia, and adrenoleukodystrophy. All patients have successfully engrafted donor cells and are currently alive. To date, since our first successful allogeneic bone marrow transplant in March 1982, we have performed 652 allogeneic hematopoietic stem cell transplants and 48 autologous hematopoietic stem cell transplants on 576 patients by December 2025. During this period, in September 1993, we successfully performed the world's first allogeneic CD34-positive cell transplant from an HLA-mismatched donor, and in October 1994, we successfully performed Japan's first umbilical cord blood transplant. In the treatment of aplastic anemia, our hospital plays a central role in Japan, having performed 107 transplants for congenital aplastic anemia (89 for Fanconi anemia, a representative disease) and 87 for acquired aplastic anemia, achieving the highest number of cases in Japan and world-class results in both categories. In addition, we have performed the highest number of transplants in Japan for congenital metabolic disorders, with 105 transplants.